Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery.
Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous …

In recent years, the development of novel recombinant virus‐like particles (VLPs) has been
generating new perspectives for the prevention of untreated and arising infectious diseases …

As ordered nanoscale architectures, viruses and virus‐like particles (VLP s) remain
unsurpassed by synthetic strategies to produce uniform and symmetric nanoparticles …

Highlights•Safety and potency of simian adenovirus vectors is now well established, most
recently in infants.•Viral vectored vaccines are effective against malaria and Ebola in field …

Virus-like particles are supra-molecular assemblages, usually icosahedral or rod-like
structures. They incorporate key immunologic features of viruses which include repetitive …

Cancers have killed millions of people in human history and are still posing a serious health
problem worldwide. Therefore, there is an urgent need for developing preventive and …

Highlights•VLP have been engineered to improve their utility as vaccine platforms.•Targeted
engineering of VLPs has enhanced immunogenicity, stability, and versatility.•Predictive …

Mosquito borne viral diseases are an emerging threat as evident from the recent outbreak of
Zika virus (ZIKV) as well as repeated outbreaks of Chikungunya (CHIKV), Yellow fever (YFV) …

Vaccines based on virus-like particles (VLPs) can induce potent B cell responses. Some non-
chimeric VLP-based vaccines are highly successful licensed products (eg, hepatitis B …

The influenza pandemic of 2009 demonstrated the inability of the established global
capacity for egg-based vaccine production technology to provide sufficient vaccine for the …